Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Common Equity (2018 - 2025)

Neurogene (NGNE) has disclosed Common Equity for 5 consecutive years, with $265.5 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Common Equity rose 93.24% year-over-year to $265.5 million, compared with a TTM value of $265.5 million through Sep 2025, up 93.24%, and an annual FY2024 reading of $310.4 million, changed N/A over the prior year.
  • Common Equity was $265.5 million for Q3 2025 at Neurogene, down from $273.3 million in the prior quarter.
  • Across five years, Common Equity topped out at $310.4 million in Q4 2024 and bottomed at $137.4 million in Q3 2024.